Try our mobile app
First disclosure from Phase 3 COMMANDS study, selected for both ASCO’s official press program and EHA’s plenary session, highlights potential of Reblozyl (luspatercept-aamt) as first-line treatment of anemia in very low- to intermediate-risk myelodysplastic syndromes
First presentation of results from primary analysis of TRANSCEND CLL 004 demonstrates benefit of Breyanzi (lisocabtagene maraleucel) in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
New TRIDENT-1 data reinforce potential of precision medicine repotrectinib in patients with locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC), including those with central nervous system metastases
Four-year data in NSCLC from CheckMate -9LA demonstrate durable long-term survival benefit for Opdivo (nivolumab) + Yervoy (ipilimumab) + platinum-based chemotherapy and three-year data from CheckMate -816 continue to demonstrate long-term clinical benefits of Opdivo + chemotherapy in patients with earlier stages of NSCLC
Bristol Myers Squibb to Host Virtual Investor Event on Tuesday, June 6, 2023, to Discuss ASCO Highlights
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the European Hematology Association (EHA) Congress, and the International Conference on Malignant Lymphoma (ICML), underscoring the company’s momentum towards delivering treatment options with the hope to transform clinical outcomes for patients. Data from more than 160 company-sponsored studies, investigator-sponsored studies and collaborations evaluating compounds spanning 20 cancer types and serious blood disorders will be featured across the three meetings, including the COMMANDS study, which has been selected for the official ASCO press program (Abstract #7003) and EHA plenary session (Abstract #S102).
“We look forward to sharing our research during ASCO, EHA and ICML, demonstrating the diversity of our assets, cutting-edge pipeline, and science-driven strategy focused on shaping the next generation of cancer care,” said Samit Hirawat, M.D., executive vice president, chief medical officer, Global Drug Development, Bristol Myers Squibb. “The breadth of data and results illustrate how we are leveraging novel technologies to develop therapies that disrupt the course of disease for patients with solid tumors, blood cancers, and blood disorders. Positive study outcomes are critical, and so is ensuring those results represent and can benefit a diverse population of patients. Our health equity commitments are enabling inclusive innovation, better science and greater reach of our medicines to the patients who need them most.”
Key data being presented by Bristol Myers Squibb at ASCO, EHA and ICML 2023 include:
Hematology
Cell Therapy
Solid Tumor
Please see below for Important Safety Information and full Prescribing Information for Reblozyl, Opdualag, Opdivo, and Opdivo+Yervoy.
Please see below for Important Safety Information and full Prescribing Information, including Boxed Warnings, for Abecma, Breyanzi and Inrebic.
Investor Event
Bristol Myers Squibb will host a virtual Investor Event on Tuesday, June 6, 2023, from 7:00-8:00 a.m. CT/8:00-9:00 a.m. ET to discuss data presented at ASCO. Company executives will provide an overview of data presented and address questions from investors and analysts.
Investors and the general public are invited to listen to a live webcast of the event at http://investor.bms.com. An archived edition of the session will be available later that day.
Summary of Presentations
Select Bristol Myers Squibb studies at the 2023 ASCO Annual Meeting include:
Abstract Title | Author | Presentation Type/# | Session Title | Session Date/Time (EDT) |
Acute Myeloid Leukemia | ||||
Implications for acute myeloid leukemia (AML) treatment and care during the COVID-19 pandemic: A Connect Myeloid Registry study. | Bart L. Scott | Poster
Abstract #7021 | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant | Monday, June 5, 2023
9:00 AM – 12:00 PM |
Gastrointestinal | ||||
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142. | Heinz-Josef Lenz | Poster
Abstract #3550 | Gastrointestinal Cancer—Colorectal and Anal | Monday, June 5, 2023
9:00 AM – 12:00 PM |
Predictive value of tumor-infiltrating lymphocyte (TIL) dynamics in the tumor microenvironment (TME) during preoperative chemoradiotherapy (CRT) on pathologic complete response (pCR) in microsatellite-stable (MSS) locally advanced rectal cancer (LARC). | Mitsuho Imai | Poster
Abstract #3608 | Gastrointestinal Cancer—Colorectal and Anal
| Monday, June 5, 2023
9:00 AM – 12:00 PM |
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649. | Yelena Y. Janjigian | Poster
Abstract #4025 | Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary | Monday, June 5, 2023
9:00 AM – 12:00 PM |
Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): 36-month results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649. | Elena Elimova | Poster
Abstract #4038
| Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary | Monday, June 5, 2023
9:00 AM – 12:00 PM |
Genitourinary | ||||
Health-related quality of life (HRQoL) of risk-based patient subgroups with advanced renal cell cancer (aRCC) treated with nivolumab plus cabozantinib (NIVO+CABO) vs sunitinib (SUN) in the CheckMate 9ER trial. | David Cella | Poster
Abstract #4527 | Genitourinary Cancer—Kidney and Bladder | Saturday, June 3, 2023
9:00 AM – 12:00 PM |
Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial. | Robert J. Motzer | Oral
Abstract #4506 | Genitourinary Cancer—Kidney and Bladder | Monday, June 5, 2023
12:30 PM – 3:30PM |
Gynecologic | ||||
Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer. | Drew W. Rasco | Poster
Abstract #5595 | Gynecologic Cancer | Monday, June 5, 2023
2:15 PM – 5:15 PM |
Efficacy and final safety analysis of pre- and co-administration of nivolumab (Nivo) with concurrent chemoradiation (CCRT) followed by Nivo maintenance therapy in patients (pts) with locally advanced cervical carcinoma (LACvCa): Results from the phase I trial, GOTIC-018. | Kazuto Nakamura | Poster
Abstract #5519 | Gynecologic Cancer | Monday, June 5, 2023
5:30 PM – 7:00 PM |
Preclinical testing of farletuzumab ecteribulin (FZEC [MORAb-202]) and MORAb-109, folate receptor α and mesothelin targeting antibody-drug conjugates (ADCs), in rare gynecologic cancers. | Cassandra Vandenberg | Publication Only
Abstract #e17634 | Gynecologic Cancer | N/A |
Head & Neck | ||||
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck. | Kevin Joseph Harrington | Poster
Abstract #TPS6106 | Head and Neck Cancer | Monday, June 5, 2023
2:15 PM – 5:15 PM |
Lymphoma | ||||
Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting. | Javid J. Moslehi | Poster
Abstract #7053 | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant | Monday, June 5, 2023
9:00 AM – 12:00 PM |
Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy. | Loretta J. Nastoupil | Poster
Abstract #7526 | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Monday, June 5, 2023
9:00 AM – 12:00 PM |
Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744. | Paul David Harker-Murray
| Poster
Abstract #7515 | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Monday, June 5, 2023
2:15 PM – 3:45 PM |
Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004. | Tanya Siddiqi | Oral
Abstract #7501 | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Tuesday, June 6, 2023
10:45 AM – 1:45 PM |
Melanoma | ||||
The validity of a machine learning algorithm in predicting response to immune checkpoint inhibitors in melanoma. | Faisal Fa’ak | Poster
Abstract #9523 | Melanoma/Skin Cancers | Saturday, June 3, 2023
2:15 PM – 5:15 PM |
Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma. | Joseph J. Sacco | Poster
Abstract #9527 | Melanoma/Skin Cancers | Saturday, June 3, 2023
2:15 PM – 5:15 PM |
Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in CheckMate 067. | F. Hodi | Poster
Abstract #9542 | Melanoma/Skin Cancers | Saturday, June 3, 2023
2:15 PM – 5:15 PM |
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD). | Dirk Schadendorf | Poster
Abstract #9552 | Melanoma/Skin Cancers | Saturday, June 3, 2023
2:15 PM – 5:15 PM |
Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIB/C/IV melanoma treated with adjuvant immunotherapy in CheckMate 238. | Mahrukh M. Syeda | Poster
Abstract #9577 | Melanoma/Skin Cancers | Saturday, June 3, 2023
2:15 PM – 5:15 PM |
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047. | Hussein A. Tawbi | Oral
Abstract #9502 | Melanoma/Skin Cancers | Monday, June 5, 2023
4:00 PM – 7:00 PM |
Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209 -76K). | Georgina V. Long | Oral
Abstract #9504 | Melanoma/Skin Cancers | Monday, June 5, 2023
4:00 PM – 7:00 PM |
Merkel Cell Carcinoma | ||||
Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic Merkel cell carcinoma (MCC) (CheckMate 358). | Shailender Bhatia | Oral
Abstract #9506 | Melanoma/Skin Cancers | Monday, June 5, 2023
4:00 PM – 7:00 PM |
Multiple Myeloma | ||||
Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM). | Julia Piasecki | Poster
Abstract #8031 | Hematologic Malignancies—Plasma Cell Dyscrasia | Monday, June 5, 2023
9:00 AM – 12:00 PM |
Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT). | Michel Delforge | Poster
Abstract #8032 | Hematologic Malignancies—Plasma Cell Dyscrasia | Monday, June 5, 2023
9:00 AM – 12:00 PM |
Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel). | Nicholas Strong | Poster
Abstract #8035 | Hematologic Malignancies—Plasma Cell Dyscrasia | Monday, June 5, 2023
9:00 AM – 12:00 PM |
EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). | Sagar Lonial | Poster
Abstract #TPS8069 | Hematologic Malignancies—Plasma Cell Dyscrasia | Monday, June 5, 2023
9:00 AM – 12:00 PM |
A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2. | Paul G. Richardson
| Poster
Abstract #TPS8070 | Hematologic Malignancies—Plasma Cell Dyscrasia | Monday, June 5, 2023
9:00 AM – 12:00 PM |
Myelodysplastic Syndrome | ||||
Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-‑naive transfusion-dependent (TD) patients (pts) with lower-‑risk myelodysplastic syndromes (LR-MDS). | Guillermo Garcia-Manero | Oral
Abstract #7003 | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant | Friday, June 2, 2023
2:00 PM – 5:00 PM |
Hematologic and transfusion outcomes in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) receiving luspatercept: Real-world assessment in the community practice setting. | Sudipto Mukherjee | Poster
Abstract #7057 | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant | Monday, June 5, 2023
9:00 AM – 12:00 PM |
Clinical outcomes by SF3B1 mutation status in patients (pts) with lower-risk myelodysplastic syndrome (LR-MDS) retreated with erythropoiesis-stimulating agents (ESAs). | Adeola Y. Makinde | Poster
Abstract #7071 | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant | Monday, June 5, 2023
9:00 AM – 12:00 PM |
A phase 2/3 trial of oral azacitidine (Oral-AZA) in patients (pts) with low- or intermediate-risk myelodysplastic syndromes (MDS). | Guillermo Garcia-Manero
| Poster
Abstract #TPS7083 | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant | Monday, June 5, 2023
9:00 AM – 12:00 PM |
Myelofibrosis | ||||
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study. | Aaron Thomas Gerds | Poster
Abstract #7016 | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant | Monday, June 5, 2023
12:30 PM – 2:00 PM |
Thoracic | ||||
Phase 2 small cell lung cancer (SCLC) cohort of a phase 1b/2 trial of a liposomal formulation of eribulin in combination with nivolumab. | Koichi Azuma | Poster
Abstract #8593 | Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | Sunday, June 4, 2023
9:00 AM – 12:00 PM |
Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial. | Jonathan Spicer | Poster
Abstract #8521 | Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | Sunday, June 4, 2023
12:30 PM – 2:00 PM |
Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1. | Jessica Jiyeong Lin | Poster
Abstract #9017 | Lung Cancer—Non-Small Cell Metastatic | Sunday, June 4, 2023
5:30 PM – 7:00 PM |
First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4‑y clinical update and outcomes by tumor histologic subtype (THS). | David Paul Carbone | Poster
Abstract #LBA9023 | Lung Cancer—Non-Small Cell Metastatic | Sunday, June 4, 2023
5:30 PM – 7:00 PM |
All abstracts except late-breaking abstracts will be available on the ASCO website at 5:00 PM EDT on Thursday, May 25. All late-breaking abstracts will be available on the ASCO website at 8:00 AM EDT on the day of the scientific session for the abstract presentation.
Select Bristol Myers Squibb studies at the 2023 EHA Congress include:
Abstract Title | Author | Presentation Type/# | Session Date/ Time (EDT) |
Acute Myeloid Leukemia | |||
Longitudinal characterization of molecular variants at remission and relapse: subanalyisis of the QUAZAR AML-001 trial. | Andrew Wei | Poster
Abstract #P411 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Disease monitoring of NPM1-mutant (mut) acute myeloid leukemia (AML) using measurable residual disease (MRD) assessments during oral azacitidine (oral-AZA) treatment (tx): a QUAZAR AML-001 subanalysis. | Gail Roboz | Poster
Abstract #P459 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
A real-world evaluation of treatment patterns and outcomes of acute myeloid leukemia induction therapies in the community setting. | Keri Maher | Poster
Abstract #P515 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Phase 1b OMNIVERSE trial: Safety and tolerability of oral azacitidine in combination with venetoclax for treatment of acute myeloid leukemia. | Shaun Fleming | Poster
Abstract #P567 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Real-world characteristics and use of antiemetic therapies among patients with acute myeloid leukemia treated with oral azacitidine maintenance therapy. | Ying Qui
| Poster
Abstract #P587 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Implications of registry data for acute myeloid leukemia (AML) treatment and care during the COVID-19 pandemic. | John Kelly | Poster
Abstract #P589 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Beta Thalassemia | |||
Effect of luspatercept on bone mineral density in patients with beta-thalassemia enrolled in the phase 3 BELIEVE trial. | Thomas D. Coates | Poster
Abstract #P1466
| Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Long-term erythroid response data from patients (pts) with non-transfusion-dependent beta-thalassemia (NTDT) receiving luspatercept in the BEYOND trial. | Ali T. Taher | Oral
Abstract #S273 | Sunday, June 11, 2023
5:30 – 6:45 AM (11:30 AM – 12:45 PM CEST) |
Alpha Thalassemia | |||
Trial in Progress: A phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of luspatercept to treat anemia in adults with alpha-thalassemia. | Vip Viprakasit | Abstract only publication
Abstract #PB2535 | N/A |
Lymphoma | |||
Economic burden in chronic lymphocytic leukemia (CLL) for patients with ≥2 prior lines of therapy including a bruton tyrosine kinase inhibitor (BTKi) and/or B-cell lymphoma 2 inhibitor (BCL2i). | Farrukh Awan | Poster
Abstract #P1696 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Qualitative interviews to describe burden in patients (pt) with third-line or later CLL/SLL with prior exposure to bruton tyrosine kinase inhibitor (BTKi) and/or B-cell lymphoma 2 inhibitor (BCL2i). | Mona L Martin | Abstract only publication
Abstract #PB2696 | N/A |
Multiple Myeloma | |||
Synergistic antitumor activity of the BCMA 2+1 T cell engager (TCE) alnuctamab (ALNUC; BMS-986349; CC-93269) and CELMoD agents in multiple myeloma (MM) preclinical models. | Bruno Paiva | Poster
Abstract #P799 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class-exposed relapsed and refractory multiple myeloma. | Marc S. Raab | Poster
Abstract #P801 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Baseline characteristics identifying patients with multiple myeloma treated with idecabtagene vicleucel (ide-cel; BB2121) who are at risk for severe/refractory inflammatory adverse events. | Yi Lin | Poster
Abstract #P809 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Soluble factors correlated with cytokine release syndrome (CRS) with IV vs subcutaneous (SC) alnuctamab (ALNUC; BMS-986349; CC-93269) in patients with relapsed/refractory multiple myeloma (RRMM). | Luciano Costa | Poster
Abstract #P825 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
| Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis by prior lines of therapy. | Saloman Manier | Poster
Abstract #P866 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Mezigdomide (MEZI) plus dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the dose-expansion phase of the CC-92480-MM-001 trial. | Nizar J. Bahlis | Poster
Abstract #P868 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Idecabtagene vicleucel (ide-cel) in patients with an inadequate response to frontline autologous stem cell transplantation (ASCT): results from KarMMa-2 cohort 2c. | Melissa Alsina | Poster
Abstract #P871 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma (RRMM): final overall survival analysis of the phase 2 MM-014 study. | Nizar J. Bahlis | Poster
Abstract #P882 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study. | Sandy W. Wong | Poster
Abstract #P883 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Patient reported outcomes in triple class exposed, relapsed/refractory multiple myeloma (TCE RRMM) patients in KarMMa-3 trial (phase 3 RCT): idecabtagene vicleucel (ide-cel) versus standard regimens. | Michel Delforge | Poster
Abstract #P905 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Treatment patterns and clinical outcomes of patients with multiple myeloma previously treated with lenalidomide and an anti-CD38 monoclonal antibody: findings from the Connect® MM disease registry. | Rafat Abonour | Poster
Abstract #P915 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Real-world clinical outcomes among triple-class exposed relapsed refractory multiple myeloma patients in US and Europe: PREAMBLE registry study. | Hartmut Goldschmidt | Poster
Abstract #P945 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
BMS-986393 (CC-95266), a G protein–coupled receptor class C group five member D (GPRC5D)–targeted CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Results from a phase 1 study. | Susan Bal | Oral
Abstract #S193 | Saturday, June 10, 2023
5:30 – 6:45 AM (11:30 AM – 12:45 PM CEST) |
Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class–exposed (tce) relapsed and refractory multiple myeloma (rrmm): a KarMMa-3 analysis in high-risk subgroups. | Krina Patel | Oral
Abstract #S195
| Saturday, June 10, 2023
10:30 – 11:45 AM (4:30 – 5:45 PM CEST) |
Elotuzumab or daratumumab in combination with pomalidomide and dexamethasone (EPd and DPd) in relapsed refractory multiple myeloma (RRMM): a network meta-analysis. | Adriana Cury | Abstract only publication
Abstract #PB2095 | N/A |
Myelodysplastic Syndromes | |||
Luspatercept versus epoetin alfa for treatment (TX) of anemia in ESA-naïve patients with lower-risk myelodysplastic syndromes(LR-MDS) patients (PTS) requiring RBC transfusions: data from the COMMANDS study. | Matteo Giovanni Della Porta | Oral plenary and special session
Abstract #S102 | Saturday, June 10, 2023
8:45 – 10:15 AM (2:45 – 4:15 PM CEST) |
Luspatercept restores effective erythropoiesis and provides superior and sustained benefit vs epoetin alfa: biomarker analysis from the phase 3 COMMANDS study. | Uwe Platzbecker | Poster
Abstract #P693 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Distinct splicing alternations associated with clinical response to luspatercept in patients with lower-risk myelodysplastic syndromes from the MEDALIST study. | Amit Verma | Poster
Abstract #P697 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Treatment patterns and outcomes among patients with lower-risk myelodysplastic syndromes receiving luspatercept in routine clinical practice in the United States. | Sudipto Mukherjee | Poster
Abstract #P733 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
First-line treatment patterns and outcomes among patients with the newly diagnosed myelodysplastic syndromes: a global, retrospective observational cohort study. | Amer M. Zeidan | Abstract only publication
Abstract #PB2010 | N/A |
Myelofibrosis | |||
Efficacy and safety of luspatercept for the treatment of anemia in patients with myelofibrosis: results from the ACE-536-MF-001 Study. | Francesco Passamonti
| Oral
Abstract #S167 | Friday, June 9, 2023
8:45 – 10:00 AM (2:45 – 4:00 PM CEST) |
Fedratinib is effective in ruxolitinib-resistant cells: clinical and preclinical correlations. | Vikas Gupta | Poster
Abstract #P997 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
Real-world treatment patterns and healthcare resource utilization in myelofibrosis patients with anemia. | John Mascarenhas | Poster
Abstract #P1059 | Friday, June 9, 2023
12:00 – 1:00 PM (6:00 – 7:00 PM CEST) |
BMS-986158, a potent BET inhibitor, as monotherapy and in combination with ruxolitinib or fedratinib in intermediate- or high-risk myelofibrosis (MF): results from a phase 1/2 study. | Haifa Kathrin Al-Ali
| Oral
Abstract #S213 | Saturday, June 10, 2023 5:30 – 6:45 AM (11:30 AM – 12:45 PM CEST) |
All EHA abstracts except late-breaking abstracts will be available on May 11. All late-breaking abstracts will be available on June 1.
Select Bristol Myers Squibb studies at the 2023 ICML Annual Meeting include:
Abstract Title | Author | Presentation Type/# | Session Title | Session Date/ Time (EDT) |
Non-Hodgkin Lymphoma | ||||
CC-99282 plus R-CHOP in patients (pts) with previously untreated aggressive B-cell lymphoma (aBCL): early safety and efficacy results from a phase 1b study. | Javier Munoz | Poster Abstract #438 | Phase I-II
| Wednesday, June 14, 2023
6:00AM – 12:00 PM (12:00 – 6:00 PM CEST)
Thursday, June 15 – Friday, June 16, 2023
4:00 AM – 12:00 PM (10:00 AM – 6:00 PM CEST) |
Open-label phase 1/2 study of CC-99282, a cereblon E3 ligase modulator (CELMoD) agent ± rituximab, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). | Jean-Marie Michot | Oral
Abstract #90 | Session 14 Novel Agents | Saturday, June 17, 2023
2:45 – 4:15 AM (9:45 – 10:15 AM CEST) |
Chronic Lymphocytic Leukemia | ||||
Health-related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso-cel in TRANSCEND CLL 004. | S.S. Kenderian | Poster
Abstract #400 | CAR-T (Cellular Therapies)
| Wednesday, June 14, 2023
6:00AM – 12:00 PM (12:00 – 6:00 PM CEST)
Thursday, June 15 – Friday, June 16, 2023
4:00 AM – 12:00 PM (10:00 AM ‒ 6:00 PM CEST) |
Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004. | Tanya Siddiqi | Oral
Abstract #26 | Session 4 CLL and Richter Syndrome
| Thursday, June 15, 2023
7:45 – 9:15 AM (1:45 – 3:15 PM CEST) |
Large B Cell Lymphoma | ||||
Comparison of overall survival of lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) adjusting for crossover in second-line (2L) R/R large B-cell lymphoma. | Franck Morschhauser | Poster
Abstract #332 | DLBCL
| Wednesday, June 14, 2023
6:00AM – 12:00 PM (12:00 – 6:00 PM CEST)
Thursday, June 15 – Friday, June 16, 2023
4:00 AM – 12:00 PM (10:00 AM – 6:00 PM CEST) |
Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line therapy in large B-cell lymphoma (TRANSFORM study): Subgroup analyses by prior therapy response. | Loretta J. Nastoupil | Oral
Abstract #138 | Session 8 “Focus on...” Large B-Cell and Double Hit Lymphomas | Thursday, June 15
11:00 AM – 12:00 PM (5:00 ‒ 6:00 PM CEST) |
All ICML accepted abstracts (except encore abstracts) will be available on June 9.
Bristol Myers Squibb: Creating a Better Future for People with Cancer
Bristol Myers Squibb is inspired by a single vision — transforming patients’ lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine, and through innovative digital platforms, are turning data into insights that sharpen their focus. Deep scientific expertise, cutting-edge capabilities and discovery platforms enable the company to look at cancer from every angle. Cancer can have a relentless grasp on many parts of a patient’s life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis to survivorship. Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.
Learn more about the science behind cell therapy and ongoing research at Bristol Myers Squibbhere.
REBLOZYL
INDICATIONS
REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate- risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN- RS-T).
REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Thrombosis/Thromboembolism
In adult patients with beta thalassemia, thromboembolic events (TEE) were reported in 8/223 (3.6%) of REBLOZYL-treated patients. TEEs included deep vein thrombosis, pulmonary embolus, portal vein thrombosis, and ischemic stroke. Patients with known risk factors for thromboembolism (splenectomy or concomitant use of hormone replacement therapy) may be at further increased risk of thromboembolic conditions. Consider thromboprophylaxis in patients at increased risk of TEE. Monitor patients for signs and symptoms of thromboembolic events and institute treatment promptly.
Hypertension
Hypertension was reported in 10.7% (61/571) of REBLOZYL-treated patients. Across clinical studies, the incidence of Grade 3 to 4 hypertension ranged from 1.8% to 8.6%. In patients with beta thalassemia with normal baseline blood pressure, 13 (6.2%) patients developed systolic blood pressure (SBP) ≥130 mm Hg and 33 (16.6%) patients developed diastolic blood pressure (DBP) ≥80 mm Hg. In adult patients with MDS with normal baseline blood pressure, 26 (29.9%) patients developed SBP ≥130 mm Hg and 23 (16.4%) patients developed DBP ≥80 mm Hg. Monitor blood pressure prior to each administration. Manage new or exacerbations of preexisting hypertension using anti-hypertensive agents.
Extramedullary Hematopoietic Masses
In adult patients with transfusion-dependent beta thalassemia, EMH masses were observed in 3.2% of REBLOZYL-treated patients, with spinal cord compression symptoms due to EMH masses occurring in 1.9% of patients (BELIEVE and REBLOZYL long-term follow-up study).
In a study of adult patients with non-transfusion-dependent beta thalassemia, a higher incidence of EMH masses was observed in 6.3% of REBLOZYL-treated patients vs. 2% of placebo-treated patients in the double-blind phase of the study, with spinal cord compression due to EMH masses occurring in 1 patient with a prior history of EMH. REBLOZYL is not indicated for use in patients with non-transfusion-dependent beta thalassemia.
Possible risk factors for the development of EMH masses in patients with beta thalassemia include history of EMH masses, splenectomy, splenomegaly, hepatomegaly, or low baseline hemoglobin (
